Clinical outcomes of ultra-long acting insulin analogues: impact on hypoglycaemia
This session will assess the comparative data on hypoglycaemic profiles of the two current ultra long-acting basal analogue insulins available outlining the differences, benefits and place in therapy.
- Attendees will be able to see the benefits of both Insulins and place in therapies
- Attendees will be helped in the design of local pathways including these insulins
- Attendees will be helped to see the differences and similarities of these two basal insulins
Prescribing information can be found here.
This promotional session has been organised by Sanofi and the speaker remunerated by Sanofi
Wednesday 14th November 2018
12:50 - 13:20